

## **SAFETY DATA SHEET**

Section 1: Identification		
Trade Name	Dabigatran etexilate capsules 75 mg, 110 mg and 150 mg	
Recommended use	Pharmaceutical Product	
Manufacturer	Hetero Labs Limited, 22-110, IDA, Unit III, Jeedimetla, Hyderabad-	
	500055, India.	
Distributor	Camber Pharmaceuticals, Inc., Piscataway, NJ 08854	
Section 2: Hazard(s) Identification		
Classification of substance or mixture	The substance is not classified ,according to the Globally Harmonized	
	system (GHS).	
Section 3: Composition/Information on Ingredients		
Ingredients	CAS	
Dabigatran etexilate	211915-06-9	
Hydroxypropyl Cellulose	9004-64-2	
Hypromellose	9004-65-3	
Sugar spheres	92004-84-7	
Talc	14807-96-6	
Tartaric acid	87-69-4	
Iron oxide red	1309-37-1	
Iron oxide yellow	1309-33-7	
Titanium dioxide	13463-67-7	
Black iron oxide	1317-61-9	
Potassium hydroxide	1310-58-3	
Propylene glycol	57-55-6	
Shellac	9000-59-3	
Strong ammonia solution	1336-21-6	
Section 4: First-Aid Measures		
After swallowing	If symptoms persist consult doctor.	
Inhalation	Supply fresh air; consult doctor in case of complaints.	
Skin Contact	Generally the product does not irritate the skin.	
Eye Contact	Rinse opened eye for several minutes under running water.	
Signs and symptoms	May cause anemia, cough, CNS depression, drowsiness, headache, heart damage, lassitude(weakness, exhaustion), liver damage, narcosis, reproductive effects, teratogenic effects. No further relevant information available.	



	n 5: Fire-Fighting Measures	
Extinguishing Media (Suitable)  Special hazards arising from the substance or mixture.	Use fire fighting measures that suit the environment. A solid water stream may be inefficient.  No further relevant information available.	
Protective equipment	No special measures required.	
Section 6: Accidental Release Measures		
Clean-up Methods	Pick up mechanically.	
Environmental Precautions:	Do not allow to enter sewers/surface or ground water.	
Personal precautions	Not required.	
Section 7: Handling and Storage		
Handling:		
Precautions for safe handling	No special measures required.	
Storage:	No further relevant information available.	
Section 8: Exposure Controls/Personal Protection		
Personal Protective Equipment: General protective and hygienic measures	The usual precautionary measures for handling chemicals should be followed.	
Protection of hands	The glove material has to be impermeable and resistant to the product /the substance /the preparation. Due to missing tests no recommendation to the glove material can be given for the product/the preparation /the chemical mixture.  Selection of the glove material on consideration of the penetration times, rates of diffusion and the degradation.	
Material of gloves	The selection of suitable gloves does not only depend on the material, but also on further marks of quality and varies from manufacturer to manufacturer.	
Penetration time of glove material	The exact break through time has to be found out by manufacturer of the protective gloves and has to be observed.	
Eye protection	Not required.	
Section 9: Physical and Chemical Properties		
Physical Form	Capsule	
Description	Dabigatran etexilate 75 mg capsules are cream opaque cap/cream opaque body size '2' HPMC capsules imprinted with 'H' on cap and 'D10' on body with black ink, filled with mixture of off-white to yellowish white pellets. The capsules are supplied in the packages listed:	
	Unit of use bottle of 60 capsules NDC 31722-621-60	
	Dabigatran etexilate 110 mg capsules are cream opaque cap/cream opaque body size '1' HPMC capsules imprinted with 'H' on cap and 'D16' on body with black ink, filled with mixture of off-white to yellowish white pellets. The capsules are supplied in the packages listed: Unit of use bottle of 60 capsules  NDC 31722-666-60	
	Blister package containing 60 capsules (10 x 6 capsule blister cards) NDC 31722-666-32	



	Dabigatran etexilate 150 mg capsules are cream opaque cap/cream opaque body size '0' HPMC capsules imprinted with 'H' on cap and 'D11' on body with black ink, filled with mixture of off-white to yellowish white pellets. The capsules are supplied in the packages listed:
	Unit of use bottle of 60 capsules NDC 31722-622-60
Section	on 10: Stability and Reactivity
Chemical stability	
Thermal decomposition/conditions to be avoided	No decomposition if used according to specifications.
Reactivity	No further relevant information available
Conditions to avoid	No further relevant information available.
Incompatible materials	Strong oxidizing agents.
Hazardous decomposition products	Carbon oxides, nitrogen oxides.
Section 11: Toxicological Information	
Additional toxicological information	When used and handled according to specifications, the product does not have any harmful effects according to our experience and the information provided to us. The substance is not subject to classification.
Section 12: Ecological Information	
Additional ecological information Water hazard class 1(self assessment)	Slightly hazardous for water.  Do not allow undiluted product or large quantities of it to reach ground water, water course or sewage system.
Section 13: Disposal Considerations	
Water treatment methods Recommendation	Smaller quantities can be disposed of with household waste.
Uncleaned packagings Recommendation	Disposal must be made according to official regulations.
Section	on 14: Transport Information
UN-Number	Not regulated
DOT,IMDG,IATA	
UN-proper shipping name	Not regulated
DOT,IMDG,IATA	
Transport hazard class(es)	Not regulated
DOT,ADN,IMDG,IATA	
Class	
Packing group	Not regulated
DOT,IMDG,IATA	
Environmental hazards	Not applicable
Special precautions for user	Not applicable
Transport in bulk according to Annex II of MARPOL73/78 and the IBC code	Not applicable
UN "model Regulation".	Not regulated



Section 15: Regulatory Information

Carcinogenic categories

**EPA** 

TLV Substance is not listed Substance is not listed Substance is not listed Substance is not listed Substance is not listed

Hazard pictograms
Signal word
None
Hazard statements
None
None

Chemical safety assessment A chemical safety Assessment has not carried out.

## **Section 16: Other Information**

Issue Date: 01-08-2024

Version: 01

**Further information** 

**Revision date: 01-08-2024** 

Revision note: Additional strength 110 mg included.

The information and recommendations in this safety data sheet are, to the best of our knowledge, accurate as of the date of issue. Nothing herein shall be deemed to create any warranty, express or implied. It is the responsibility of the user to determine the applicability of this information and the suitability of the material or product for any particular purpose.

Hetero Pharma Private Limited shall not be held liable for any damage resulting from handling or from contact with the above product. Hetero Pharma Private Limited reserves the right to revise this SDS.